journal article·2019-03

Dual growth factor-immobilized bioactive injection material for enhanced treatment of glottal insufficiency

Young Hwan Choi, Hee-Jin Ahn, Mi Ri Park, Mi-Jung Han, Jin Ho Lee, Seong Keun Kwon

Acta Biomaterialia· Volume 86
Publisher page

Abstract

With increasing demand for treatment of glottal insufficiency, several injection materials have been examined. However, biological resorption, degradation of injected materials, and the subsequent need to perform multiple injections still remain major clinical problems. In this study, we fabricated two different growth factor (GF) [single basic fibroblast growth factor (bFGF), single hepatocyte growth factor (HGF), or dual bFGF/HGF]-immobilized polycaprolactone (PCL)/Pluronic F127 microspheres. These materials were investigated for their potential use as bioactive injection laryngoplasty agents. HGF was found to be continuously released over 20 days and the bFGF was found to be continuously released over 25 days, as demonstrated by ELISA assay. Human vocal fold fibroblasts (hVFFs) showed significantly higher proliferative ability on dual GF-immobilized microspheres. GF-immobilized microspheres (bFGF, HGF, and dual GF) were injected into paralyzed vocal folds of New Zealand white rabbits. Through endoscopic observation and H&E staining, we identified that the microspheres remained localized at the injection site, resulting in constant volume augmentation of the paralyzed vocal fold without significant loss of the initial volume after 4 weeks. The expression of genes related to the extracellular matrix (ECM) in the vocal fold was upregulated by dual GF-immobilized microspheres. Furthermore, dual GF-immobilized microspheres inhibited muscle degeneration and upregulation of myogenic-related genes. In conclusion, dual GF-immobilized microspheres passively augmented the volume of the paralyzed vocal fold while actively inducing ECM synthesis at the injected vocal fold and preserving muscle tissue. Dual GF-immobilized microspheres could be a new and promising injection material for paralyzed vocal folds. STATEMENT OF SIGNIFICANCE: Limitation of prolonged augmentation of vocal fold and degeneration of vocal fold tissue still remain as major clinical problems in the treatment of vocal fold paralysis. Herein, we fabricated the polycaprolactone (PCL)/Pluronic F127 microspheres to augment volume of paralyzed vocal folds. On top of that, we additionally immobilized the growth factors (bFGF, HGF, or dual bFGF/HGF) on the surface of these microspheres. We highlight the efficacy of the dual GF-immobilized microspheres which augmented the volume of the paralyzed vocal fold passively, induced ECM synthesis actively at the injected vocal fold and preserved laryngeal muscle tissue. Our results suggest that the dual GF-immobilized microsphere could be a new promising injection material for injection laryngoplasty to treat paralyzed vocal fold.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Voice and Speech Disorders · Tracheal and airway disorders · Dysphagia Assessment and Management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (74)

Show source-provided references
1. Tuberculosis presenting as bilateral vocal fold palsy: case report and review of otolaryngological manifestations of tuberculosis10.1017/S002221511100185X ↗
2. Bilateral vocal cord paralysis in a patient with Parkinson’s disease
3. Relationship among glottal area, static supraglottic compression, and laryngeal function studies in unilateral vocal fold paresis and paralysis10.1016/j.jvoice.2003.11.005 ↗
4. Correlation between vocal functions and glottal measurements in patients with unilateral vocal fold paralysis10.1097/00005537-199706000-00012 ↗
5. A comparison of outcomes in interventions for unilateral vocal fold paralysis: a systematic review10.1002/lary.25739 ↗
6. Injection laryngoplasty10.1016/j.otc.2005.10.008 ↗
7. Prevention of polydimethylsiloxane microsphere migration using a mussel-inspired polydopamine coating for potential application in injection therapy10.1371/journal.pone.0186877 ↗
8. Human adipose tissue derived extracellular matrix and methylcellulose hydrogels augments and regenerates the paralyzed vocal fold10.1371/journal.pone.0165265 ↗
9. Prevention of anterior glottis web with hyaluronic acid derivatives in rabbit model10.1002/lary.26089 ↗
10. Vocal fold augmentation with beta glucan hydrogel cross-linked by gamma irradiation for enhanced duration of effect: in vivo animal study10.1155/2015/592372 ↗
11. Evaluation of the poly(lactic-co-glycolic acid)/pluronic F127 for injection laryngoplasty in rabbits10.1177/0194599814549527 ↗
12. Polycaprolactone spheres and theromosensitive Pluronic F127 hydrogel for vocal fold augmentation: in vivo animal study for the treatment of unilateral vocal fold palsy10.1002/lary.23879 ↗
13. Tissue engineering-based therapeutic strategies for vocal fold repair and regeneration10.1016/j.biomaterials.2016.08.054 ↗
14. Denervation changes in mammalian striated muscle10.1136/jnnp.13.3.159 ↗
15. Remodeling of the vascular bed and progressive loss of capillaries in denervated skeletal muscle10.1002/(SICI)1097-0185(20000301)258:3<292::AID-AR9>3.0.CO;2-N ↗
16. Interrelations of myogenic response, progressive atrophy of muscle fibers, and cell death in denervated skeletal muscle10.1002/ar.1155 ↗
17. Vocal fold augmentation with injectable polycaprolactone microspheres/pluronic F127 hydrogel: long-term in vivo study for the treatment of glottal insufficiency10.1371/journal.pone.0085512 ↗
18. Heparin and heparan sulfate: structure and function10.1039/b100916h ↗
19. Heparin protects basic and acidic Fgf from inactivation10.1002/jcp.1041280317 ↗
20. Heparin structure and interactions with basic fibroblast growth factor10.1126/science.271.5252.1116 ↗
21. The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study10.1042/BST0371201 ↗
22. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity10.1111/j.1432-1033.1996.0295n.x ↗
23. Hairpin loop and second kringle domain are essential sites for heparin binding and biological activity of hepatocyte growth factor10.1016/S0021-9258(17)42231-9 ↗
24. Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications10.1016/j.actbio.2013.07.031 ↗
25. Growth factor therapy for vocal fold scarring in a canine model10.1177/000348940411301002 ↗
26. Prevention of vocal fold scarring by topical injection of hepatocyte growth factor in a rabbit model10.1097/00005537-200403000-00030 ↗
27. Regeneration of aged vocal folds with basic fibroblast growth factor in a rat model: a preliminary report10.1177/000348940511400409 ↗
28. Drug delivery system of hepatocyte growth factor for the treatment of vocal fold scarring in a canine model10.1177/000348940711601008 ↗
29. Regeneration of aged vocal fold: first human case treated with fibroblast growth factor (Retraction of vol. 119, pg 197, 2009)
30. Morphological and functional changes of human vocal fold fibroblasts with hepatocyte growth factor10.1177/000348940311201206 ↗
31. Roles of hepatocyte growth factor and transforming growth factor beta1 in production of extracellular matrix by canine vocal fold fibroblasts10.1097/00005537-200301000-00027 ↗
32. Single injection of basic fibroblast growth factor to treat severe vocal fold lesions and vocal fold paralysis10.1002/lary.25315 ↗
33. Fibroblasts in human vocal fold mucosa10.1080/00016489950181800 ↗
34. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting10.1016/j.jconrel.2010.01.017 ↗
35. Preparation of TGF-beta1-conjugated biodegradable pluronic F127 hydrogel and its application with adipose-derived stem cells10.1016/j.jconrel.2010.06.020 ↗
36. Novel fabrication of PCL porous beads for use as an injectable cell carrier system10.1002/jbm.b.31313 ↗
37. Colorimetric method for the assay of heparin content in immobilized heparin preparations10.1016/0003-2697(80)90679-X ↗
38. Vascular endothelial growth factor immobilized in collagen scaffold promotes penetration and proliferation of endothelial cells10.1016/j.actbio.2007.12.011 ↗
39. Novel isolation and biochemical characterization of immortalized fibroblasts for tissue engineering vocal fold lamina propria10.1089/ten.tec.2008.0390 ↗
40. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors10.1016/j.biomaterials.2005.11.043 ↗
41. The interaction of the transforming growth factor-beta s with heparin heparan sulfate is isoform-specific10.1074/jbc.272.29.18000 ↗
42. The importance of drug delivery systems in tissue engineering10.1016/S1461-5347(00)00242-X ↗
43. Fibroblast growth factors: biology, function, and application for tissue regeneration
44. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine10.2183/pjab.86.588 ↗
45. Evaluation of injection augmentation treatment of hyaluronic acid based materials on rabbit vocal folds viscoelasticity10.1007/s10856-005-0531-2 ↗
46. Glottic Insufficiency: Vocal Fold Paralysis, Paresis, and Atrophy, Operative Techniques in Laryngology, Springer, Berlin Heidelberg, Berlin, Heidelberg, 2008, pp. 29–35.
47. Histological study of injected autologous fascia in the paralyzed canine vocal fold10.1097/00005537-200012000-00006 ↗
48. Production of heparin-functionalized hydrogels for the development of responsive and controlled growth factor delivery systems10.1016/j.jconrel.2007.04.019 ↗
49. Photo-crosslinkable and biodegradable Pluronic/heparin hydrogels for local and sustained delivery of angiogenic growth factor10.1002/jbm.a.31271 ↗
50. The stability factor: importance in formulation development10.2174/1389201023378229 ↗
51. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor10.1002/jbm.a.30843 ↗
52. Lamina propria replacement therapy with cultured autologous fibroblasts for vocal fold scars10.1016/j.otohns.2004.07.010 ↗
53. Bioengineered vocal fold mucosa for voice restoration10.1126/scitranslmed.aab4014 ↗
54. Effects of growth factors on extracellular matrix production by vocal fold fibroblasts in 3-dimensional culture10.1089/ten.2006.12.3365 ↗
55. Effects of basic fibroblast growth factor on rat vocal fold fibroblasts10.1177/000348941011901008 ↗
56. Comparative histology and vibration of the vocal folds: implications for experimental studies in microlaryngeal surgery10.1097/00005537-200005000-00011 ↗
57. Interspecies comparison of mucosal wave properties using high-speed digital imaging10.1002/lary.20884 ↗
58. Use of the rabbit larynx in an excised larynx setup10.1016/j.jvoice.2012.08.004 ↗
59. Histologic and rheologic characterization of vocal fold scarring10.1016/S0892-1997(02)00078-4 ↗
60. Characterization of chronic vocal fold scarring in a rabbit model10.1016/j.jvoice.2003.06.001 ↗
61. In vivo engineering of the vocal fold extracellular matrix with injectable hyaluronic acid hydrogels: early effects on tissue repair and biomechanics in a rabbit model10.1177/000348940511400902 ↗
62. Tissue-engineered vocal fold mucosa implantation in rabbits10.1177/0194599816628501 ↗
63. Vocal fold paresis
64. Differential collagen distribution in the mitral valve and its influence on biomechanical behaviour
65. Relationship between the axial periodicity and staining of collagen by the Masson trichrome procedure10.1007/BF01007005 ↗
66. Novel porous aortic elastin and collagen scaffolds for tissue engineering10.1016/j.biomaterials.2003.12.019 ↗
67. Staining abnormalities of dermal collagen in cats with cutaneous asthenia or acquired skin fragility as demonstrated with Masson's trichrome stain10.1046/j.1365-3164.1998.00074.x ↗
68. Prevention of vocal fold scarring by local application of basic fibroblast growth factor in a rat vocal fold injury model10.1002/lary.26138 ↗
69. Recombinant IGF-I: past, present and future10.1016/j.ghir.2016.01.002 ↗
70. Therapeutic potential of growth factors for aging voice10.1097/01.mlg.0000149450.37640.db ↗
71. Regenerative effects of basic fibroblast growth factor on extracellular matrix production in aged rat vocal folds10.1177/000348940911800805 ↗
72. Regeneration of aged rat vocal folds using hepatocyte growth factor therapy10.1002/lary.20497 ↗
73. Optimal concentration of hepatocyte growth factor for treatment of the aged rat vocal fold10.1002/lary.21816 ↗
74. Vocal fold fibroblast response to growth factor treatment is age dependent: results from an in vitro study10.1016/j.jvoice.2013.11.005 ↗